Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7349339 | 0.84 | PDE3B (0.49) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL3401752 | 0.72 | TSHR (0.51) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL29354025 | 0.72 | TSHR (0.51) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL21483641 | 0.71 | TSHR (0.62) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL18128200 | 0.70 | TSHR (0.54) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| 2-Methyl-D-Diboa SCHEMBL13135829 | 0.70 | ALDH1A1 (0.54) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL13091065 | 0.67 | TSHR (0.54) | TSHRALDH1A1HTTMEN1KMT2A | |
| SCHEMBL9787326 | 0.67 | TSHR (0.60) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL30806327 | 0.66 | ALDH1A1 (0.42) | TSHRALDH1A1L3MBTL1HTTMEN1 | |
| SCHEMBL30806501 | 0.66 | ALDH1A1 (0.42) | TSHRALDH1A1L3MBTL1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | TSHR 1185/4885ALDH1A1 1361/4885L3MBTL1 899/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | TSHR 1169/4885ALDH1A1 1396/4885L3MBTL1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.